查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1423782

全球皮肤和系统性利甚曼病市场 - 全球产业分析、规模、份额、成长、趋势、预测 (2031) - 按药物类别、按给药途径、按适应症、按分销管道、按地区

Cutaneous and Systemic Leishmaniasis Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:
出版日期: | 出版商: Fairfield Market Research | 英文 215 Pages | 商品交期: 2-5个工作天内

价格
简介目录

在 2024-2031 年预测期内，全球皮肤和系统性利甚曼病市场规模呈上升趋势。 这种成长可归因于推动市场扩张的几个关键因素。

推动皮肤和系统性利甚曼病市场成长的关键因素之一是透过联合药物治疗实现的令人印象深刻的临床治癒率。 多种药物的组合已被证明非常有效，有些组合可以完全治癒。 这一充满希望的方面预计将在整个预测期内维持市场成长。

皮肤和系统性利甚曼病市场的许多利益相关者正在大力投资研发，旨在开发创新疗法。 正在进行的各种药物和治疗的临床试验显示出有希望的结果，并有望为皮肤和系统性利甚曼病的治疗开闢新的可能性。

世界各国政府正大力投资医疗基础设施，为市场成长做出贡献。 此外，私人健康保险提供者提供优惠的报销政策，允许患者选择最适合自己需求的计划，使治疗更加容易。

由于药物昂贵，治疗皮肤和系统性利甚曼病的费用仍然相对较高，而且这些治疗可能会产生严重的副作用。 然而，正在进行的研究和开发工作预计将在未来产生更具成本效益和更安全的治疗方法。

皮肤和系统性利甚曼病市场竞争激烈，其特征是大公司主导该行业。 市场进入者正在采取技术联盟、经销商协议、研发强化和产品发布等新的创新策略，以满足不断增长的需求并建立区域市场优势。

本报告研究了全球皮肤和系统性利甚曼病市场，按药物类别、给药途径、适应症、分销管道、区域趋势和市场进入提供了市场概述。我们提供以下资讯：这样做的公司的竞争趋势。

目录

第 1 章执行摘要

第二章市场概述

  • 市场定义与细分
  • 市场动态
  • 价值链分析
  • 波特五力分析
  • 新冠肺炎 (COVID-19) 影响分析
  • 乌克兰和俄罗斯之间衝突的影响
  • 经济概况
  • 杵分析

第 3 章 2018-2031 年全球皮肤与系统性利甚曼病市场展望

  • 2018-2031 年全球皮肤和系统性利甚曼病市场展望（按药物类别、价值（十亿美元））
  • 2018-2031 年全球皮肤和系统性利甚曼病市场展望（按给药途径）、价值（十亿美元）
  • 2018-2031 年全球皮肤和系统性利甚曼病市场展望（按适应症、价值（十亿美元））
  • 2018-2031 年全球皮肤和系统性利甚曼病市场展望（按分销管道）、价值（美元）
  • 2018-2031 年全球皮肤和系统性利甚曼病市场展望（按地区、价值（十亿美元））

第 4 章北美皮肤与系统性利甚曼病市场展望，2018-2031

第 5 章欧洲皮肤与系统性利甚曼病市场前景，2018-2031

第 6 章亚太地区皮肤与系统性利甚曼病市场展望，2018-2031

第 7 章拉丁美洲皮肤与系统性利甚曼病市场展望，2018-2031 年

第 8 章中东和非洲皮肤和系统性利甚曼病市场展望，2018-2031 年

第九章竞争态势

  • 药物类别和适应症的热图
  • 2023 年公司市占率分析
  • 竞争对手仪表板
  • 公司简介
    • Gilead Sciences, Inc.
    • Profounda Pharmaceuticals
    • Knight Therapeutics Inc.
    • Janssen Global Services, LLC
    • Albert David Ltd
    • Jubilant Life Sciences Ltd.
    • Novartis AG
    • Sanofi
    • Endo Pharmaceuticals Inc
    • Bristol-Myers Squibb Company
    • United Biotech Pvt. Ltd.

第 10 章附录

简介目录

The global Cutaneous and Systemic Leishmaniasis market is on an upward trajectory over the forecast period 2024-2031. This growth can be attributed to several key factors that are driving the market's expansion.

High Clinical Cure Rate with Combinational Drug Therapy

One of the pivotal factors fueling the growth of the Cutaneous and Systemic Leishmaniasis market is the impressive clinical cure rate achieved through combinational drug therapy. The use of various drug combinations has proven to be highly effective, with some combinations even resulting in complete cures. This promising aspect is expected to sustain the market's growth throughout the forecast period.

Increased Investments for Research And Development

Numerous stakeholders in the Cutaneous and Systemic Leishmaniasis market are making substantial investments in research and development efforts aimed at developing innovative treatment alternatives. Ongoing clinical trials for a wide range of drugs and therapies show promising outcomes, which are anticipated to open up new opportunities for treating cutaneous and systemic leishmaniasis.

Favorable Reimbursement Policies

Governments worldwide are significantly investing in healthcare infrastructure, contributing to the growth of the market. Additionally, private health insurance providers are offering favorable reimbursement policies, allowing patients to choose plans that best suit their needs, further facilitating access to treatment.

However, the market does face some challenges:

High Cost of Treatment and Chances Of Side Effects

The cost of treating Cutaneous and Systemic Leishmaniasis remains relatively high due to expensive drugs, and these treatments may have serious side effects. Nevertheless, ongoing research and development efforts are expected to yield more cost-effective and safer treatment options in the future.

Impact of COVID-19

The COVID-19 pandemic initially led to a decrease in demand for Cutaneous & Systemic Leishmaniasis treatment due to healthcare facilities' overwhelming focus on managing the pandemic. However, as the situation improved in 2021, demand for these treatments started to rebound.

Competitive Analysis

The Cutaneous and Systemic Leishmaniasis market is fiercely competitive and is characterized by major players dominating the industry. Market participants are embracing new and innovative strategies, including technological collaborations, distributorship agreements, increased research and development, and product launches, to meet growing demand and establish their dominance in regional markets.

Key Companies Profiled

  • Gilead Sciences, Inc.
  • Profounda Pharmaceuticals
  • Knight Therapeutics Inc.
  • Janssen Global Services, LLC
  • Albert David Ltd
  • Jubilant Life Sciences Ltd.
  • Novartis AG
  • Sanofi
  • Endo Pharmaceuticals Inc
  • Bristol-Myers Squibb Company
  • United Biotech Pvt. Ltd.

As the Cutaneous & Systemic Leishmaniasis market continues to grow and evolve, these key players are at the forefront of driving advancements in research, development, and access to treatment, ensuring a brighter future for those affected by this disease.

Cutaneous and Systemic Leishmaniasis Market Categorization

Cutaneous and Systemic Leishmaniasis Market by By Drug Class

  • Pentavalent Antimonials
  • Antifungal Drugs
  • Anti-Lesihmanial/Antimicrobial Drugs

Cutaneous and Systemic Leishmaniasis Market By Route of Administration

  • Oral
  • Injectable
  • Topical

Cutaneous and Systemic Leishmaniasis Market By Indication

  • Cutaneous Leishmaniasis
  • Mucosal Leishmaniasis
  • Visceral Leishmaniasis

Cutaneous and Systemic Leishmaniasis Market By Distribution Channel

  • Hospital Pharmacies,
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

Cutaneous and Systemic Leishmaniasis Market by Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa (MEA)

Table of Contents

1. Executive Summary

  • 1.1. Global Cutaneous and Systemic Leishmaniasis Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Cutaneous and Systemic Leishmaniasis Market Outlook, 2018 - 2031

  • 3.1. Global Cutaneous and Systemic Leishmaniasis Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Pentavalent Antimonials
      • 3.1.1.2. Antifungal Drugs
      • 3.1.1.3. Anti-Lesihmanial/Antimicrobial Drugs
  • 3.2. Global Cutaneous and Systemic Leishmaniasis Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Oral
      • 3.2.1.2. Injectable
      • 3.2.1.3. Topical
  • 3.3. Global Cutaneous and Systemic Leishmaniasis Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Cutaneous Leishmaniasis
      • 3.3.1.2. Mucosal Leishmaniasis
      • 3.3.1.3. Visceral Leishmaniasis
  • 3.4. Global Cutaneous and Systemic Leishmaniasis Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. Hospital Pharmacies,
      • 3.4.1.2. Retail Pharmacies
      • 3.4.1.3. Drug Stores
      • 3.4.1.4. Online Pharmacies
  • 3.5. Global Cutaneous and Systemic Leishmaniasis Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.5.1. Key Highlights
      • 3.5.1.1. North America
      • 3.5.1.2. Europe
      • 3.5.1.3. Asia Pacific
      • 3.5.1.4. Latin America
      • 3.5.1.5. Middle East & Africa

4. North America Cutaneous and Systemic Leishmaniasis Market Outlook, 2018 - 2031

  • 4.1. North America Cutaneous and Systemic Leishmaniasis Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Pentavalent Antimonials
      • 4.1.1.2. Antifungal Drugs
      • 4.1.1.3. Anti-Lesihmanial/Antimicrobial Drugs
  • 4.2. North America Cutaneous and Systemic Leishmaniasis Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Oral
      • 4.2.1.2. Injectable
      • 4.2.1.3. Topical
  • 4.3. North America Cutaneous and Systemic Leishmaniasis Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Cutaneous Leishmaniasis
      • 4.3.1.2. Mucosal Leishmaniasis
      • 4.3.1.3. Visceral Leishmaniasis
  • 4.4. North America Cutaneous and Systemic Leishmaniasis Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. Hospital Pharmacies,
      • 4.4.1.2. Retail Pharmacies
      • 4.4.1.3. Drug Stores
      • 4.4.1.4. Online Pharmacies
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis
  • 4.5. North America Cutaneous and Systemic Leishmaniasis Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.5.1. Key Highlights
      • 4.5.1.1. U.S. Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 4.5.1.2. U.S. Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 4.5.1.3. U.S. Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 4.5.1.4. U.S. Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 4.5.1.5. Canada Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 4.5.1.6. Canada Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 4.5.1.7. Canada Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 4.5.1.8. Canada Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Cutaneous and Systemic Leishmaniasis Market Outlook, 2018 - 2031

  • 5.1. Europe Cutaneous and Systemic Leishmaniasis Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Pentavalent Antimonials
      • 5.1.1.2. Antifungal Drugs
      • 5.1.1.3. Anti-Lesihmanial/Antimicrobial Drugs
  • 5.2. Europe Cutaneous and Systemic Leishmaniasis Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Oral
      • 5.2.1.2. Injectable
      • 5.2.1.3. Topical
  • 5.3. Europe Cutaneous and Systemic Leishmaniasis Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Cutaneous Leishmaniasis
      • 5.3.1.2. Mucosal Leishmaniasis
      • 5.3.1.3. Visceral Leishmaniasis
  • 5.4. Europe Cutaneous and Systemic Leishmaniasis Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Hospital Pharmacies,
      • 5.4.1.2. Retail Pharmacies
      • 5.4.1.3. Drug Stores
      • 5.4.1.4. Online Pharmacies
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis
  • 5.5. Europe Cutaneous and Systemic Leishmaniasis Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.5.1. Key Highlights
      • 5.5.1.1. Germany Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.5.1.2. Germany Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.5.1.3. Germany Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.4. Germany Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.5.1.5. U.K. Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.5.1.6. U.K. Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.5.1.7. U.K. Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.8. U.K. Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.5.1.9. France Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.5.1.10. France Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.5.1.11. France Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.12. France Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.5.1.13. Italy Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.5.1.14. Italy Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.5.1.15. Italy Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.16. Italy Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.5.1.17. Turkey Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.5.1.18. Turkey Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.5.1.19. Turkey Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.20. Turkey Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.5.1.21. Russia Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.5.1.22. Russia Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.5.1.23. Russia Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.24. Russia Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.5.1.25. Rest of Europe Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.5.1.26. Rest of Europe Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.5.1.27. Rest of Europe Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.28. Rest of Europe Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Cutaneous and Systemic Leishmaniasis Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Cutaneous and Systemic Leishmaniasis Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Pentavalent Antimonials
      • 6.1.1.2. Antifungal Drugs
      • 6.1.1.3. Anti-Lesihmanial/Antimicrobial Drugs
  • 6.2. Asia Pacific Cutaneous and Systemic Leishmaniasis Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Oral
      • 6.2.1.2. Injectable
      • 6.2.1.3. Topical
  • 6.3. Asia Pacific Cutaneous and Systemic Leishmaniasis Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Cutaneous Leishmaniasis
      • 6.3.1.2. Mucosal Leishmaniasis
      • 6.3.1.3. Visceral Leishmaniasis
  • 6.4. Asia Pacific Cutaneous and Systemic Leishmaniasis Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. Hospital Pharmacies,
      • 6.4.1.2. Retail Pharmacies
      • 6.4.1.3. Drug Stores
      • 6.4.1.4. Online Pharmacies
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis
  • 6.5. Asia Pacific Cutaneous and Systemic Leishmaniasis Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.5.1. Key Highlights
      • 6.5.1.1. China Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.5.1.2. China Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.5.1.3. China Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.4. China Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.5.1.5. Japan Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.5.1.6. Japan Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.5.1.7. Japan Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.8. Japan Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.5.1.9. South Korea Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.5.1.10. South Korea Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.5.1.11. South Korea Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.12. South Korea Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.5.1.13. India Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.5.1.14. India Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.5.1.15. India Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.16. India Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.5.1.17. Southeast Asia Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.5.1.18. Southeast Asia Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.5.1.19. Southeast Asia Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.20. Southeast Asia Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.5.1.21. Rest of Asia Pacific Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.5.1.22. Rest of Asia Pacific Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.5.1.23. Rest of Asia Pacific Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.24. Rest of Asia Pacific Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Cutaneous and Systemic Leishmaniasis Market Outlook, 2018 - 2031

  • 7.1. Latin America Cutaneous and Systemic Leishmaniasis Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Pentavalent Antimonials
      • 7.1.1.2. Antifungal Drugs
      • 7.1.1.3. Anti-Lesihmanial/Antimicrobial Drugs
  • 7.2. Latin America Cutaneous and Systemic Leishmaniasis Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Oral
      • 7.2.1.2. Injectable
      • 7.2.1.3. Topical
  • 7.3. Latin America Cutaneous and Systemic Leishmaniasis Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Cutaneous Leishmaniasis
      • 7.3.1.2. Mucosal Leishmaniasis
      • 7.3.1.3. Visceral Leishmaniasis
  • 7.4. Latin America Cutaneous and Systemic Leishmaniasis Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Hospital Pharmacies,
      • 7.4.1.2. Retail Pharmacies
      • 7.4.1.3. Drug Stores
      • 7.4.1.4. Online Pharmacies
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis
  • 7.5. Latin America Cutaneous and Systemic Leishmaniasis Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.5.1. Key Highlights
      • 7.5.1.1. Brazil Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 7.5.1.2. Brazil Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 7.5.1.3. Brazil Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.5.1.4. Brazil Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.5.1.5. Mexico Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 7.5.1.6. Mexico Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 7.5.1.7. Mexico Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.5.1.8. Mexico Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.5.1.9. Argentina Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 7.5.1.10. Argentina Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 7.5.1.11. Argentina Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.5.1.12. Argentina Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.5.1.13. Rest of Latin America Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 7.5.1.14. Rest of Latin America Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 7.5.1.15. Rest of Latin America Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.5.1.16. Rest of Latin America Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Cutaneous and Systemic Leishmaniasis Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Cutaneous and Systemic Leishmaniasis Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Pentavalent Antimonials
      • 8.1.1.2. Antifungal Drugs
      • 8.1.1.3. Anti-Lesihmanial/Antimicrobial Drugs
  • 8.2. Middle East & Africa Cutaneous and Systemic Leishmaniasis Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Oral
      • 8.2.1.2. Injectable
      • 8.2.1.3. Topical
  • 8.3. Middle East & Africa Cutaneous and Systemic Leishmaniasis Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Cutaneous Leishmaniasis
      • 8.3.1.2. Mucosal Leishmaniasis
      • 8.3.1.3. Visceral Leishmaniasis
  • 8.4. Middle East & Africa Cutaneous and Systemic Leishmaniasis Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. Hospital Pharmacies,
      • 8.4.1.2. Retail Pharmacies
      • 8.4.1.3. Drug Stores
      • 8.4.1.4. Online Pharmacies
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis
  • 8.5. Middle East & Africa Cutaneous and Systemic Leishmaniasis Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.5.1. Key Highlights
      • 8.5.1.1. GCC Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 8.5.1.2. GCC Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.5.1.3. GCC Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.5.1.4. GCC Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.5.1.5. South Africa Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 8.5.1.6. South Africa Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.5.1.7. South Africa Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.5.1.8. South Africa Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.5.1.9. Egypt Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 8.5.1.10. Egypt Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.5.1.11. Egypt Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.5.1.12. Egypt Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.5.1.13. Nigeria Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 8.5.1.14. Nigeria Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.5.1.15. Nigeria Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.5.1.16. Nigeria Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.5.1.17. Rest of Middle East & Africa Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 8.5.1.18. Rest of Middle East & Africa Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.5.1.19. Rest of Middle East & Africa Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.5.1.20. Rest of Middle East & Africa Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Drug Class vs Indication Heatmap
  • 9.2. Company Market Share Analysis, 2023
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Gilead Sciences, Inc.
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. Profounda Pharmaceuticals
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Product Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. Knight Therapeutics Inc.
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Product Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. Janssen Global Services, LLC
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Product Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. Albert David Ltd
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Product Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Jubilant Life Sciences Ltd.
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Product Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. Novartis AG
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Product Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development
    • 9.4.8. Sanofi
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Product Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Development
    • 9.4.9. Endo Pharmaceuticals Inc
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Product Portfolio
      • 9.4.9.3. Financial Overview
      • 9.4.9.4. Business Strategies and Development
    • 9.4.10. Bristol-Myers Squibb Company
      • 9.4.10.1. Company Overview
      • 9.4.10.2. Product Portfolio
      • 9.4.10.3. Financial Overview
      • 9.4.10.4. Business Strategies and Development
    • 9.4.11. United Biotech Pvt. Ltd.
      • 9.4.11.1. Company Overview
      • 9.4.11.2. Product Portfolio
      • 9.4.11.3. Financial Overview
      • 9.4.11.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations